Site 'Tertiary' Navigation:

Page 'Breadcrumb' Navigation:

Press Releases

 
Press Releases
  Date Title and Summary View
Jan 7, 2014
SALT LAKE CITY, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced changes to the Company's Board of Directors, including the appointments of Dr. Stephen Hill, Mr. Jeffrey Fink, and Dr. R. Dana Ono, and the retirements of Chairman Dr. William Higuchi and Mr. Gordhan Patel. D...
Dec 13, 2013
SALT LAKE CITY, Dec. 13, 2013 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced that Dr. William I. Higuchi will receive an honorary Doctor of Science degree from the University of Michigan at the winter commencement ceremony, Sunday December 15, 2013. The University notes Dr. Higuc...
Dec 6, 2013
SALT LAKE CITY, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the underwriters of its previously announced public offering have fully exercised their option to purchase an additional 223,800 shares of Lipocine common stock at a price of $8.25 per share, for additional gross pro...
Nov 27, 2013
SALT LAKE CITY, UT (GLOBENEWSWIRE) - November 27, 2013 - Lipocine Inc. ("Lipocine") (OTCQB⁄OTCBB:LPCN), a specialty pharmaceutical company, today announced the pricing of an underwritten public offering of 1,492,000 shares of its common stock at a price to the public of $8.25 per share. The gross proceeds from this offering to Lipocine are ex...
Sep 16, 2013
SALT LAKE CITY (BUSINESS WIRE - September 16, 2013) Lipocine Inc. ("Lipocine") (OTCQB⁄OTCBB:LPCN), a specialty pharmaceutical company, announced today that Morgan Brown has joined the Company as Executive Vice President and Chief Financial Officer ("CFO"). Mr. Brown has more than 20 years of financial and accounting experience, including over...
Aug 22, 2013
SALT LAKE CITY (BUSINESS WIRE - August 22, 2013) Lipocine Inc.(OTCQB⁄OTCBB:LPCN), a specialty pharmaceutical company, announced today that it has changed its trading symbol from OTCBB:MBARD to OTCQB⁄OTCBB:LPCN. On July 24, 2013, Lipocine successfully completed a reverse merger with Marathon Bar Corp. The combined company is focused sole...
Jul 31, 2013
SALT LAKE CITY (BUSINESS WIRE - July 31, 2013) Lipocine, Inc. (OTCBB:MBARD), a specialty pharmaceutical company, announced today that it has closed its previously announced private placement with institutional investors. In the private placement, Lipocine issued and sold approximately 6.3 million shares of its common stock at $...
Jul 26, 2013
SALT LAKE CITY (BUSINESS WIRE - July 26, 2013) Lipocine, Inc. (OTCBB:MBARD), a specialty pharmaceutical company, announced today that it has entered into securities purchase agreements with gross proceeds of $38.0 million for the issuance and sale of approximately 6.3 million shares of its common stock at $6.00 per share to inst...
May 7, 2013
Press Release: LifeSci Advisors (NEW YORK, NY--Marketwired - May 7, 2013) - LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Lipocine Inc., a private biotechnology focused on becoming the leader in sec...
Apr 5, 2013
(Salt Lake City, April 5, 2013) - Lipocine Inc. (www.lipocine.com, a biopharmaceutical company focused on developing innovative oral hormone therapies for men's and women's health, today announced favorable Phase I results for LPCN 1111. LPCN 1111, a novel prodrug of testosterone, uses the Company's proprietary Lipâ€&...
Page: FirstPrevious ...
10
NextLast
= add release to Briefcase